glp-1 chronic kidney disease Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes GLP-1 Receptor Agonists and Kidney
Description
27 At the 1-, 2-, and 3-year timepoints, they found that the GLP-1 RA cohort had a significantly lower risk of all three outcomes compared with metformin users
Available from: Hamed K, Alosaimi MN, Ali BA, Alghamdi A, Alkhashi T, Alkhaldi SS, et al
Other signs include vomiting undigested food, feeling full after a few bites, and abdominal bloating
Abdominal tenderness, injection site reactions, thyroid changes, and signs of dehydration are best assessed in person
Replace lost fluids with water or electrolyte drinks to prevent dehydration
